Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes

This study addresses the need for simple and minimally invasive assessment of the tumour immune microenvironment in hepatocellular carcinoma, revealing key compartmentalised immunotherapy targets that are not predictable from blood. Findings are important for researchers, clinicians and patients to guide personalised immune checkpoint inhibitor selection and the development of novel approaches to block immunosuppressive neutrophils in order to improve on limited responses to current hepatocellular carcinoma therapies. We demonstrate the potential of rapid fine needle aspirate-based immune profiling to be integrated into larger studies, including clinical trials, to guide personalised selection of patients for existing and future immune checkpoint inhibitors, provide insights into mechanisms of primary and secondary resistance, and inform the development of novel immunotherapy targets.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-10-17
DOI
https://doi.org/10.1016/j.jhepr.2025.101637
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes

Jessica Davies, Stephanie Kucykowicz, Gloryanne Aidoo-Micah, Vishnu Naidu et al.
1 citations
JHEP Reports
Cancer Immunotherapy and Biomarkers
1.05
article

Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes

Jessica Davies, Stephanie Kucykowicz, Gloryanne Aidoo-Micah, Vishnu Naidu, Leo Swadling, Tim Meyer, Upkar S. Gill, Mariana O. Diniz, Yiya Zhong, Mala K. Maini, Nathalie Schmidt, Edward D. Green, Laura J. Pallett, Alexa Childs, Rushabh Shah, Daniel Brown Romero, Tate Mckinnon-Snell, Sayani Khara
article en
1 citations

Abstract

This study addresses the need for simple and minimally invasive assessment of the tumour immune microenvironment in hepatocellular carcinoma, revealing key compartmentalised immunotherapy targets that are not predictable from blood. Findings are important for researchers, clinicians and patients to guide personalised immune checkpoint inhibitor selection and the development of novel approaches to block immunosuppressive neutrophils in order to improve on limited responses to current hepatocellular carcinoma therapies. We demonstrate the potential of rapid fine needle aspirate-based immune profiling to be integrated into larger studies, including clinical trials, to guide personalised selection of patients for existing and future immune checkpoint inhibitors, provide insights into mechanisms of primary and secondary resistance, and inform the development of novel immunotherapy targets.

JHEP ReportsVol. 8(1)
Queen Mary University of London (GB), The Royal Free Hospital (GB), CRUK Lung Cancer Centre of Excellence (GB), University College London (GB)
Openalex Percentile: Top 17%
Cancer Immunotherapy and Biomarkers
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.